Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch

Clinical and Vaccine Immunology

Volumn 20, Issue 9, 2013, Pages 1433-1439

  Quan, Fu Shi ^a   Kim, Yeu Chun ^b   Song, Jae Min ^c   Hwang, Hye Suk ^f   Compans, Richard W ^d   Prausnitz, Mark R ^e   Kang, Sang Moo ^f  

^a Kyung Hee University Hospital   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Sungshin Women's University   (South Korea)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Georgia Institute of Technology   (United States)

^f GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA A H1N1 VIRUS LIKE PARTICLE VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 6; PLACEBO; STABILIZING AGENT; TREHALOSE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG STABILITY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LUNG PARENCHYMA; MATERIAL COATING; MEMORY CELL; MICRONEEDLE; MICRONEEDLE PATCH; MICROTECHNOLOGY; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRAL CLEARANCE; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS LOAD;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PLASMA CELLS; SPLEEN; SURVIVAL ANALYSIS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL LOAD;

EID: 84884688641     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00251-13     Document Type: Article

References (43)

1. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. 2010. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr. 2:RRN1153. doi:10.1371/currents.RRN1153.
2. Osterholm MT. 2005. Preparing for the next pandemic. N. Engl. J. Med. 352:1839-1842.
3. Galarza JM, Latham T, Cupo A. 2005. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18:244-251.
4. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-5759.
5. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878.
6. Quan FS, Huang C, Compans RW, Kang SM. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81:3514-3524.
7. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C. 2009. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27:530-541.
8. Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO. 2011. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin. Vaccine Immunol. 18:2010-2017.
9. Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, Chen LM, Hogan RJ, Donis RO, Compans RW, Kang SM. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405:165-175.
10. Kang SM, Song JM, Compans RW. 2011. Novel vaccines against influenza viruses. Virus Res. 162:31-38.
11. Kang SM, Song JM, Quan FS, Compans RW. 2009. Influenza vaccines based on virus-like particles. Virus Res. 143:140-146.
12. Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ. 1991. Keratinocytes as initiators of inflammation. Lancet 337:211-214.
13. Enioutina EY, Visic D, Daynes RA. 2000. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18: 2753-2767.
14. Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak V, Berthier-Vergnes O, de Saint-Vis B, Caux C, Dezutter-Dambuyant C, Lebecque S, Valladeau J. 2006. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 177:7959-7967.
15. Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ. 2004. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 23:794-801.
16. Kendall M, Mitchell T, Wrighton-Smith P. 2004. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 37:1733-1741.
17. Vrdoljak A, McGrath MG, Carey JB, Draper SJ, Hill AV, O'Mahony C, Crean AM, Moore AC. 2012. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J. Control. Release 159:34-42.
18. van der Maaden K, Jiskoot W, Bouwstra J. 2012. Microneedle technologies for (trans)dermal drug and vaccine delivery. J. Control. Release 161: 645-655.
19. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. 2009. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 27:6932-6938.
20. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. 2009. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One 4:e7152. doi:10.1371/journal.pone.0007152.
21. Song JM, Kim YC, Barlow PG, Hossain MJ, Park KM, Donis RO, Prausnitz MR, Compans RW, Kang SM. 2010. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 88:244-247.
22. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, Murthy N, Compans RW, Skountzou I, Prausnitz MR. 2010. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16:915-920.
23. Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, Pan L, Skountzou I, Gill HS, Prausnitz MR, Yang C, Compans RW. 2009. Immunization by vaccinecoated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. U. S. A. 106:7968-7973.
24. Kim YC, Park JH, Prausnitz MR. 2012. Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev. 64:1547-1568.
25. Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. 2010. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J. Control. Release 147:326-332.
26. Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, Compans RW, Kang SM. 2010. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol. 84:7760-7769.
27. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. 2010. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J. Control. Release 142: 187-195.
28. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Jacob J, Prausnitz MR, Compans RW, Skountzou I. 2011. Serological memory and longterm protection to novel H1N1 influenza virus after skin vaccination. J. Infect. Dis. 204:582-591.
29. Quan FS, Vunnava A, Compans RW, Kang SM. 2010. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 5:e9161. doi:10.1371/journal.pone.0009161.
30. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. 2010. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS Pharm Sci Tech 11:1193-1201.
31. Quan FS, Compans RW, Cho YK, Kang SM. 2007. Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine 25:272-282.
32. Quan FS, Compans RW, Nguyen HH, Kang SM. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82:1350-1359.
33. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, Hotard A, Sherrill TP, Peebles RS, Jr, Moore ML. 2011. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J. Virol. 85: 5782-5793.
34. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG. 2010. Newcastle disease virus-like particles containing respiratory syncytial virus Gprotein induced protection in BALB/c mice, with no evidence of immunopathology. J. Virol. 84:1110-1123.
35. Song JM, Kim YC, Lipatov AS, Pearton M, Davis CT, Yoo DG, Park KM, Chen LM, Quan FS, Birchall JC, Donis RO, Prausnitz MR, Compans RW, Kang SM. 2010. Microneedle delivery of H5N1 influenza viruslike particles to the skin induces long-lasting B-and T-cell responses in mice. Clin. Vaccine Immunol. 17:1381-1389.
36. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, Prausnitz MR, Compans RW, Skountzou I. 2012. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci. Rep. 2:357. doi:10.1038/srep00357.
37. Ansaldi F, Durando P, Icardi G. 2011. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin. Biol. Ther. 11:415-427.
38. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. 2010. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: randomized, controlled, phase III trial. Hum. Vaccines 6:346-354.
39. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M. 2008. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198:650-658.
40. Haynes L, Swain SL. 2006. Why aging T cells fail: implications for vaccination. Immunity 24:663-666.
41. Liard C, Munier S, Joulin-Giet A, Bonduelle O, Hadam S, Duffy D, Vogt A, Verrier B, Combadiere B. 2012. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J. Invest. Dermatol. 132:615-625.
42. Liu WM, van der Zeijst BA, Boog CJ, Soethout EC. 2011. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum. Vaccines 7(Suppl):94-98.
43. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. 2010. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J. Infect. Dis. 201:190-198.